Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01282
|
|||||
| Drug Name |
Naratriptan
|
|||||
| Synonyms |
Amerge (TN); Amerge, Naramig,Naratriptan; Colatan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; Naramig; Naramig (TN); Naratriptan (INN); Naratriptanum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Migraine Headaches [ICD11: 8A80] | Approved | [1] | |||
| Therapeutic Class |
Vasoconstrictor Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H25N3O2S
|
|||||
| Canonical SMILES |
CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
|
|||||
| InChI |
InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
|
|||||
| InChIKey |
AMKVXSZCKVJAGH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 121679-13-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 335.5 | Topological Polar Surface Area | 73.6 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9994
, 591979
, 4406062
, 7980085
, 8152740
, 14802133
, 29223537
, 46507243
, 46530540
, 48416313
, 49984092
, 50126335
, 50340505
, 57322272
, 85209198
, 92721601
, 93166470
, 96024943
, 103396287
, 103966995
, 104306415
, 118043420
, 124757290
, 125001918
, 125164094
, 125339313
, 126619011
, 126661482
, 126731399
, 127427940
, 134221895
, 134338167
, 135035417
, 135650691
, 135692164
, 137002440
, 139157587
, 143500462
, 144116266
, 152035273
, 152253555
, 152344169
, 160964291
, 164830541
, 174006312
, 175268422
, 176253695
, 179116807
, 196105283
, 210279333
|
|||||
| ChEBI ID |
ChEBI:7478
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Naratriptan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.